Agilent Technologies Welcomes Soriot and Brown to Board, Shares Drop 3.45%

By Bobby Samwell • Wednesday, May 21 15:31 • Permanent Link

Agilent Technologies Inc. (NYSE: A) has announced the election of Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, to its Board of Directors, effective May 21, 2025. Soriot brings decades of leadership experience in the pharmaceutical industry, having served as CEO of AstraZeneca since 2012 and previously holding executive roles at Genentech and Roche. Brown, on the other hand, is a seasoned financial and strategic adviser with deep experience across the life-sciences and consumer-health industries, having held executive and board member positions at various organizations.

The company also bid farewell to Heidi Kunz, who retired from the Board of Directors after more than 20 years of service. Kunz joined the Board in 2000, at the company’s inception. Agilent expressed gratitude for Kunz’s service, with President and CEO Padraig McDonnell thanking her for her decades of contributions to the company and Koh Boon Hwee, chair of the Agilent Board, referring to Kunz as "a foundational member" of the Agilent Board.

Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Following these announcements, the company's shares moved -3.45%, and are now trading at a price of $109.56. For the full picture, make sure to review 's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.